Fbxo7 Inhibition to Stabilize Pink1 and Protect Mitochondria
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies fail to increase Pink1 protein levels in cells, which are crucial for maintaining mitochondrial function and preventing neurodegenerative disorders and inflammation, as Pink1 deficiency leads to mitochondrial dysfunction and enhanced inflammatory responses.
Innovation Solution
Development of a small molecule inhibitor, BC1464, that disrupts the interaction between Fbxo7 and Pink1, stabilizing Pink1 protein levels and preventing its degradation, thereby reducing mitochondrial injury and inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Fbxo7 is present to mediate mitophagy, then damaged mitochondria are cleared, but Pink1 protein levels decrease due to degradation
Solution Approach 1:
The patent introduces small molecule compounds as intermediaries that bind to Fbxo7 and prevent its interaction with Pink1. This mediator approach allows Fbxo7 to continue its normal mitophagy function while blocking the harmful degradation of Pink1, thus resolving the contradiction between mitochondrial quality control and Pink1 protein stability
Solution Approach 2:
The patent changes the binding parameters of Fbxo7 by introducing small molecule ligands that alter its substrate recognition properties. These compounds modify the interaction parameters between Fbxo7 and Pink1, preventing ubiquitination while maintaining Fbxo7's ability to recognize damaged mitochondria through other substrates
2Reliability
If Pink1 levels are increased to maintain mitochondrial function, then neuroprotection is achieved, but current therapies cannot increase Pink1 levels
Solution Approach 1:
The patent replaces the mechanical/protein-based approach of directly administering Pink1 or its precursors with a small molecule chemical system. These compounds act as molecular tools that indirectly increase Pink1 levels by inhibiting its degradation, making the therapy more feasible and stable for pharmaceutical development
Solution Approach 2:
Small molecule compounds serve as intermediaries that translate the therapeutic goal of increasing Pink1 levels into a practical solution. These molecules bind to Fbxo7 and modulate its activity, providing a stable, orally administrable approach to achieve neuroprotection through Pink1 stabilization
3Productivity
If Pink1 is degraded by Fbxo7-mediated ubiquitination, then protein turnover is regulated, but neuroprotection and anti-inflammatory activity are reduced
Solution Approach 1:
The patent applies local quality modification by introducing small molecules that specifically alter the interaction between Fbxo7 and Pink1 without affecting Fbxo7's overall function. The compounds create a localized change in the Fbxo7 binding interface, allowing selective prevention of Pink1 degradation while maintaining other physiological functions
Solution Approach 2:
The patent converts the harmful effect of Fbxo7-mediated Pink1 degradation into a beneficial outcome by using small molecules to block this specific interaction. The same Fbxo7 protein, which causes harm through Pink1 degradation, becomes the target of therapeutic intervention, transforming its pathogenic role into a treatable condition
Data Source
AI summary
A method for treating a neurodegenerative disease or an inflammatory disorder in a subject, comprising administering to the subject in need thereof, a compound, or a pharmaceutically acceptable salt thereof, of formula II:wherein each of R3-R7 is independently H, halogen, optionally-substituted alkyl, amino, alkoxy or hydroxy;R8 is an optionally-substituted heterocycloalkyl; anda is 0 to 3.